Skip to main content
TipRanks
Go Ultimate75% OFF

Natural Beauty Bio-Technology (0157) AI Stock Analysis

0 Followers
HK:0157

Natural Beauty Bio-Technology

(HKEX:0157)

Select Model
Rating:52Neutral
Price Target:HKD 0.47â–²(8.14% Upside)
Action:reiterated
Date:11/12/26

The score is primarily constrained by persistent cash burn and weak cash conversion, despite revenue recovery, renewed profitability, and a solid equity base. Technical momentum is mixed, while the negative P/E and absence of dividend support further limit the outlook.

Positive Factors
2025 Revenue ReboundThe 2025 revenue rebound indicates renewed demand for the company’s beauty and skincare offering after a period of stagnation. If sustained, stronger sales can improve operating leverage, support brand distribution, and provide a broader base for rebuilding profitability over the next several quarters.
Negative Factors
Persistent Cash BurnPersistent negative operating and free cash flow is the clearest durability concern because reported earnings are not converting into cash. Continued cash burn can increase funding needs, restrict investment flexibility, and make the recent earnings recovery less dependable unless cash generation improves.

Natural Beauty Bio-Technology (0157) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-15%-10%-5%0%5%10%15%HK:0157-15.69%EWH+8.92%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 100.11M
Dividend Yield
―
Average Volume (3M)
115.19K
Price to Earnings (P/E)
-15.0
Beta (1Y)
-0.10
Revenue Growth
13.43%
EPS Growth
7.72%
Country
Hong Kong
Employees
597
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

Natural Beauty Bio-Technology Business Overview & Revenue Model

Company Description

Natural Beauty Bio-Technology Limited operates as an investment holding company, supplying skincare products and a comprehensive range of services across the People's Republic of China, Taiwan, and other global regions. Under its "Natural Beauty" bra...

Natural Beauty Bio-Technology Financial Statement Overview

Summary

Revenue grew 17% and profitability returned in 2025, while the equity base remained solid and leverage manageable. However, profitability is still low and persistent negative operating and free cash flow materially weaken financial quality.

Income Statement

65Positive

Balance Sheet

75Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue523.38M538.83M353.65M336.01M335.88M487.81M
Gross Profit227.26M293.34M202.33M200.34M165.33M281.80M
EBITDA4.98M66.15M-65.50M22.91M15.09M85.23M
Net Income-57.48M10.58M-103.61M-15.11M-30.47M35.26M
Balance Sheet
Total Assets1.01B931.55M772.93M882.58M883.53M937.16M
Cash, Cash Equivalents and Short-Term Investments116.16M112.12M116.51M166.81M168.61M197.08M
Total Debt424.66M319.30M212.13M186.29M143.48M129.07M
Total Liabilities587.05M457.56M325.34M308.06M286.07M279.24M
Stockholders Equity423.52M473.98M447.59M574.52M597.46M657.92M
Cash Flow
Free Cash Flow-136.88M-93.91M-54.96M-47.39M-35.98M4.67M
Operating Cash Flow-58.33M-25.66M-13.75M21.72M8.33M42.78M
Investing Cash Flow-74.73M-68.95M-40.17M-67.61M-38.77M-31.21M
Financing Cash Flow169.03M84.61M15.34M42.63M13.21M10.42M

Natural Beauty Bio-Technology Technical Analysis

Technical Analysis SentimentNegative
Last Price0.43

Price Trends

50DMA0.44Negative
100DMA0.45Negative
200DMA0.47Negative

Market Momentum

MACD-0.00Negative
RSI45.25Neutral
STOCH80.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0157, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.44, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 45.25 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0157.

Natural Beauty Bio-Technology Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

HK:0157 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1044HK:104475OutperformHKD 25.38B8.7910.98%7.33%2.19%10.78%
HK:2145HK:214571OutperformHKD 9.05B11.2125.77%6.18%23.19%-22.44%
HK:3828HK:382870OutperformHKD 466.46M5.486.06%10.16%2.24%-39.98%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
HK:0157HK:015752NeutralHKD 860.90M-14.98-12.81%―13.43%7.72%
HK:6993HK:699333UnderperformHKD 15.85B-173.78-1.21%6.32%-2.44%81.73%

* Consumer Defensive Sector Average

Performance Comparison

-75%-50%-25%0%25%HK:0157HK:1044HK:3828HK:2145HK:6993HK:6883Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:0157 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:0157Natural Beauty Bio-Technology 0.43-0.08-15.69%
HK:1044Hengan International Group Co 21.86-3.80-14.82%
HK:3828Ming Fai International Holdings 0.64-0.23-26.61%
HK:2145Shanghai Chicmax Cosmetics Co., Ltd. Class H22.72-58.13-71.90%
HK:6993Blue Moon Group Holdings Ltd.2.850.249.03%
HK:6883Eternal Beauty Holdings Limited2.030.052.53%

Natural Beauty Bio-Technology Corporate Events

Natural Beauty Bio-Technology Wins Unanimous Backing for Multi-Year Eastern and ET Media Deals

Aug 24, 2026

Natural Beauty Bio-Technology Limited announced that shareholders have unanimously approved seven cooperation and supply agreements with various Eastern group and ET New Media partners at an extraordinary general meeting in Taipei. The resolutions, a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026